Stock Watch: The Pandemic Still Permeates Through Q3 Earnings
In Addition To Currency And Capacity Issues
Executive Summary
While big tech is suffering from a return to normality after the pandemic, big pharma always had a recovery in its base business to return to. But after the third-quarter earnings season, it seems both base and pandemic pharmaceutical businesses are still co-existing for now.
You may also be interested in...
Stock Watch: Swelling Obesity Sales Boost Post-Pandemic Diabetes Drug Growth
The evolution of new drugs to treat diabetes has enabled some diabetes franchises to shrug off biosimilar competition to insulins. But is some of the growth of therapies for diabetes and obesity a result of the pandemic?
Stock Watch: Merck And Pfizer Reclaim Pharmaceutical Defensiveness
Merck grew sales, increased financial guidance and beat analysts’ expectations, noting a base business recovery from the pandemic. Pfizer increased guidance and beat expectations for different reasons.
GSK’s Blenrep Hit By Trial Failure, Raising Questions About Its Future In The Myeloma Market
The DREAMM-3 study was meant to be a confirmatory study for Blenrep, and its failure raises concerns over its use in earlier lines of therapy and the possibility that it could be removed from the market.